Capricor治疗 CAPR 深 沪
已收盘 10-31 16:00:00 美东时间
6.51
+0.300
+4.83%
华盛通- 最 高6.54
- 今 开6.40
- 成交量 142.56万股
- 最 低 6.16
- 昨 收 6.21
- 总市值 2.98亿
- 52周最高 20.75
- 市盈率 静 --
- 换手率 3.12%
- 52周最低 5.68
- 委 比 -84.45%
- 总股本 4571.70万
- 历史最高 171.50
- 量 比 0.93
- 振 幅 6.12%
- 历史最低 0.88
- 每 手 1
- 风险率 3.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Capricor Therapeutics announced it will release its third-quarter 2025 financial results on November 10, 2025, followed by a conference call and webcast at 4:30 p.m. ET. The event will discuss financial performance and recent corporate updates. Participants can join via toll-free numbers or webcast. The company, focused on developing cell and exosome-based therapies for rare diseases, is advancing Deramiocel for Duchenne muscular dystrophy and ex...
10-31 13:15
Why Capricor Therapeutics Stock Is Surging Today
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics.
09-25 23:16
Capricor Issues BLA Update For DMD Cell Therapy Deramiocel Following FDA Type A Meeting Post-CRL; HOPE-3 Pivotal Trial Topline Data Expected Mid-Q4 2025 To Support BLA Resubmission
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET
09-25 19:18
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $24 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $24 price target.
09-11 23:16
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
09-03 18:21
CAPR Lawsuit Alert! Class Action Lawsuit Against Capricor Therapeutics
Aclass actionlawsuit was filed againstCapricor Therapeutics (...
09-02 10:08
Capricor Therapeutics Announces First Subjects Dosed In Phase 1 Clinical Trial Evaluating Its StealthX Exosome-Based Vaccine
First-in-human trial of Capricor's StealthX™ vaccine initiated under HHS's Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID)SAN DIEGO, Aug. 18, 2025
08-18 21:14
Capricor Therapeutics Q2 EPS $(0.57) Misses $(0.46) Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.46) by 23.11 percent. This is a 62.86 percent decrease over losses of $(0.35) per
08-12 05:24
